Showing 8751-8760 of 9872 results for "".
- Melanoma Rates Up as Overall US Cancer Incidence Fallshttps://practicaldermatology.com/news/20130123-melanoma_rates_up_as_overall_us_cancer_incidence_falls/2459629/While incidence rates are declining for most cancer sites, they are increasing among both men and women for melanoma of the skin and cancers of the liver, thyroid, and pancreas. Overall cancer incidence rates decreased slightly in males (by 0.6% per year) and were stable in females in the most recen
- Allergan, Inc. to Acquire MAP Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130123-allergan_inc_to_acquire_map_pharmaceuticals_inc/2459632/Allergan, Inc. and MAP Pharmaceuticals, Inc. entered into a definitive merger agreement whereby Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25.00 pe
- BOTOX Receives FDA Approval for Overactive Bladderhttps://practicaldermatology.com/news/20130121-botox_receives_fda_approval_for_overactive_bladder/2459633/The US FDA just approved BOTOX (onabotulinumtoxinA) from Allergan, Inc. for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency in adults who have had an inadequate response to or are intol
- Modernizing Medicine Completes $12 Million Capital Raisehttps://practicaldermatology.com/news/20130111-modernizing_medicine_completes_12_million_capital_raise/2459639/Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific EMR application, completed a $12 million capital raise, with a combination of equity capital and a senior bank debt facility. The company plans to use the funding to, among other things, acc
- Winter Rosacea Treatmentshttps://practicaldermatology.com/news/20130108-winter_rosacea_treatments/2459646/Winter weather and the associated heating systems can easily aggravate sensitive and rosacea-prone skin. With Rosacea Awareness Month coming up this April, the following products can help sooth and calm the redness and irritation associated with rosacea.
- DermOne Acquires Atlantic Dermatologyhttps://practicaldermatology.com/news/20130107-dermone_acquires_atlantic_dermatology/2459647/DermOne closed on the acquisition of Atlantic Dermatology of Wilmington, NC on December 31, 2012. Atlantic Dermatology specializes in cosmetic, laser, medical, and surgical dermatolo
- Perrigo Company Acquires Cobrek Pharmaceuticals, Inc.https://practicaldermatology.com/news/20130102-perrigo_company_acquires_cobrek_pharmaceuticals_inc/2459651/Perrigo Company signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals, Inc. for approximately $45 million on a cash-free and debt-free basis. The merge concludes a four-year collaborative partnership responsi
- AMBI Now Part of Valeant Pharmaceuticalshttps://practicaldermatology.com/news/20121221-ambi_now_part_of_valeant_pharmaceuticals/2459653/Johnson & Johnson has sold the AMBI brand to Valeant Pharmaceuticals North America. Valeant is a multinational, pharmaceutical/OTC company based in Bridgewater, NJ.
- Results Released from Phase 2 Trial of IMO-3100 in Plaque Psoriasishttps://practicaldermatology.com/news/20121219-results_released_from_phase_2_trial_of_imo-3100_in_plaque_psoriasis/2459655/In a recent study, Idera Pharmaceuticals reported that 48 percent of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in
- PreCision Dermatology Adds to Board of Directorshttps://practicaldermatology.com/news/20121211-precision_dermatology_adds_to_board_of_directors/2459660/PreCision Dermatology, Inc. appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 27 years. Most recently, as the Executive Vice Pr